$550 Million FDA Fund Approved In Cures Bill, Paid For With Oil Reserves
This article was originally published in The Gray Sheet
Executive Summary
A House panel agreed 51-0 to approve 21st Century Cures legislation, including a $550 million, five-year fund to cover some of the FDA mandates in the bill, but not the device reforms. Reform spending would be offset by the sale of eight million barrels of oil from the Strategic Petroleum Reserve.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.